Brokerages Expect Genmab A/S (NASDAQ:GMAB) to Announce $0.10 Earnings Per Share

Wall Street analysts predict that Genmab A/S (NASDAQ:GMABGet Rating) will announce $0.10 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have provided estimates for Genmab A/S’s earnings, with estimates ranging from $0.02 to $0.26. Genmab A/S reported earnings of $0.27 per share in the same quarter last year, which would indicate a negative year over year growth rate of 63%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Genmab A/S will report full year earnings of $0.77 per share for the current financial year, with EPS estimates ranging from $0.63 to $0.87. For the next financial year, analysts expect that the business will report earnings of $1.10 per share, with EPS estimates ranging from $0.91 to $1.57. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Genmab A/S.

Genmab A/S (NASDAQ:GMABGet Rating) last released its earnings results on Wednesday, February 16th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.13 by $0.04. Genmab A/S had a net margin of 35.58% and a return on equity of 14.23%. The company had revenue of $402.74 million for the quarter, compared to analyst estimates of $387.16 million.

A number of equities research analysts have issued reports on the stock. SVB Leerink cut their price target on shares of Genmab A/S from $42.00 to $39.00 and set a “market perform” rating on the stock in a report on Thursday, February 17th. Morgan Stanley cut their price target on shares of Genmab A/S from $33.00 to $30.00 and set an “underweight” rating on the stock in a report on Tuesday, April 12th. Zacks Investment Research lowered shares of Genmab A/S from a “hold” rating to a “sell” rating in a report on Thursday, January 20th. HC Wainwright reissued a “buy” rating and issued a $47.00 price target on shares of Genmab A/S in a report on Thursday, March 17th. Finally, UBS Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, March 16th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $425.50.

A number of institutional investors have recently bought and sold shares of GMAB. Liberty Wealth Management LLC boosted its position in Genmab A/S by 285.6% during the 3rd quarter. Liberty Wealth Management LLC now owns 671 shares of the company’s stock valued at $28,000 after acquiring an additional 497 shares in the last quarter. Covestor Ltd bought a new stake in Genmab A/S during the 4th quarter valued at approximately $37,000. Cordasco Financial Network boosted its position in Genmab A/S by 40.8% during the 3rd quarter. Cordasco Financial Network now owns 915 shares of the company’s stock valued at $40,000 after acquiring an additional 265 shares in the last quarter. Bessemer Group Inc. boosted its position in Genmab A/S by 50.3% during the 4th quarter. Bessemer Group Inc. now owns 1,156 shares of the company’s stock valued at $46,000 after acquiring an additional 387 shares in the last quarter. Finally, Captrust Financial Advisors boosted its position in Genmab A/S by 23.2% during the 3rd quarter. Captrust Financial Advisors now owns 1,414 shares of the company’s stock valued at $62,000 after acquiring an additional 266 shares in the last quarter. 5.92% of the stock is currently owned by institutional investors and hedge funds.

GMAB stock opened at $28.32 on Tuesday. Genmab A/S has a 52 week low of $27.42 and a 52 week high of $49.07. The firm’s fifty day moving average is $34.97 and its 200 day moving average is $36.82. The firm has a market cap of $18.62 billion, a P/E ratio of 38.79, a P/E/G ratio of 1.34 and a beta of 0.98.

Genmab A/S Company Profile (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.